Search Results - "MOTZER, R. J"

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma by Motzer, R J, Escudier, B, Bukowski, R, Rini, B I, Hutson, T E, Barrios, C H, Lin, X, Fly, K, Matczak, E, Gore, M E

“…Background: Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (⩾30 months) were investigated in sunitinib-treated…”
Get full text

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma by Albiges, L., Chamming's, F., Duclos, B., Stern, M., Motzer, R.J., Ravaud, A., Camus, P.

“…The administration of mammalian target of rapamycin (mTOR) inhibitors can give rise to a potentially life-threatening adverse event, often referred to as…”
Get full text

Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials by Molina, A.M, Lin, X, Korytowsky, B, Matczak, E, Lechuga, M.J, Wiltshire, R, Motzer, R.J

“…Abstract Background Retrospective analyses were performed in patients with metastatic renal cell carcinoma (mRCC) to characterise the objective response (OR)…”
Get full text

Targeted therapy for metastatic renal cell carcinoma by PATEL, P. H, CHAGANTI, R. S. K, MOTZER, R. J

“…Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide…”
Get full text

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial by Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I

“…Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously…”
Get full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors by Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

“…Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC)…”
Get full text

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma by Patil, S., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Négrier, S., Kim, S.T., Huang, X., Motzer, R.J.

“…Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial…”
Get full text

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies by Voss, M.H., Bastos, D.A., Karlo, C.A., Ajeti, A., Hakimi, A.A., Feldman, D.R., Hsieh, J.J., Molina, A.M., Patil, S., Motzer, R.J.

“…The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in…”
Get full text

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study by Calvo, E, Escudier, B, Motzer, R.J, Oudard, S, Hutson, T.E, Porta, C, Bracarda, S, Grünwald, V, Thompson, J.A, Ravaud, A, Kim, D, Panneerselvam, A, Anak, O, Figlin, R.A

“…Abstract Introduction In the phase III RECORD-1 trial (ClinicalTrials.gov: NCT00410124 ), patients with metastatic renal cell carcinoma (mRCC) who progressed…”
Get full text

Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors by Zarbo, A., Belum, V.R., Sibaud, V., Oudard, S., Postow, M.A., Hsieh, J.J., Motzer, R.J., Busam, K.J., Lacouture, M.E.

“…Summary Cytotoxic T‐lymphocyte‐associated protein‐4, programmed cell death protein and programmed cell death protein ligand 1 monoclonal antibodies (immune…”
Get full text

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma by Hutson, T E, Bukowski, R M, Rini, B I, Gore, M E, Larkin, J M, Figlin, R A, Barrios, C H, Escudier, B, Lin, X, Fly, K, Martell, B, Matczak, E, Motzer, R J

“…Background: We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients. Methods: Data were pooled…”
Get full text

Testicular Germ-Cell Cancer by Bosl, George J, Motzer, Robert J

“…Approximately 95 percent of malignant tumors arising in the testis are germ-cell tumors, a term that indicates their origin in primordial germ cells. Germ-cell…”
Get full text

Systemic therapy for renal cell carcinoma by Motzer, R J, Russo, P

“…We review the status of systemic therapy for patients with advanced renal cell carcinoma. A literature search was performed on MEDLINE and CANCERLIT to…”
Get more information

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma by Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J

“…Background: In a randomized phase III trial of sunitinib vs interferon-alfa (IFN- α ) in metastatic renal cell carcinoma (mRCC), better baseline quality of…”
Get full text

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis by Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J

“…Background: In a randomised phase III trial, sunitinib significantly improved efficacy over interferon- α (IFN- α ) as first-line therapy for metastatic renal…”
Get full text

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α by Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J

“…Background: In a randomised phase III trial of treatment-naive patients with metastatic renal cell carcinoma, sunitinib showed significant improvement in…”
Get full text

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma by MOTZER, R. J, MAZUMDAR, M, BACIK, J, BERG, W, AMSTERDAM, A, FERRARA, J

“…To identify prognostic factors and a model predictive for survival in patients with metastatic renal-cell carcinoma (RCC). The relationship between…”
Get full text

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma by Négrier, S, Bushmakin, A.G, Cappelleri, J.C, Korytowsky, B, Sandin, R, Charbonneau, C, Michaelson, M.D, Figlin, R.A, Motzer, R.J

“…Abstract Background To determine suitability of progression-free survival (PFS) as a surrogate end-point for overall survival (OS), we evaluated the…”
Get full text

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma by Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.

“…The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib…”
Get full text

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor by Belum, V.R, Benhuri, B, Postow, M.A, Hellmann, M.D, Lesokhin, A.M, Segal, N.H, Motzer, R.J, Wu, S, Busam, K.J, Wolchok, J.D, Lacouture, M.E

“…Abstract Background Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but they have…”
Get full text